Background <p>The aim of this study was to systematically assess and discuss literature on the impact of visual impairment (VI) in combination with specific mental health disorders (MHDs), i.e. personality disorders (including antisocial, borderline and dependent personality disorder), autism spectrum disorder (ASD), obsessive-compulsive disorder and psychotic disorders, on daily functioning.</p> Methods <p>A systematic review was performed following the PRISMA-statement. The databases PubMed, Embase, CINAHL, PsycINFO, Cochrane library, and Web of Science were searched for relevant publications up to December 20th, 2024. Quality assessment was conducted following the criteria of the PHO MetaQAT. Thematic content analysis was performed to indicate the impact of VI and the chosen MHDs on daily functioning.</p> Results <p>Twenty-two relevant publications were found. Twenty-one publications described the impact of the combination of VI and ASD and sometimes additional disorders, and focused on children, predominantly in school settings. One publication addressed VI and psychosis. The impact on daily functioning was described according to age and MHD, and categorized by five main themes: (1) psychological functioning, (2) social functioning, (3) physical functioning, (4) school performance, and (5) parental and clinical support. One publication had ‘sufficient’ and ‘good’ ratings on validity, while all others had at least one ‘insufficient’ or ‘unclear’ rating.</p> Conclusions <p>A limited number of publications on the combined impact of VI and MHDs on daily functioning were found. Publications primarily focused on VI and ASD in children. Uncertainty about the impact remains due to a lack of high-quality publications. The gap in evidence calls for future research to address the challenges in supporting people with VI and MHDs.</p> Clinical trial number <p>Not applicable.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

The impact of visual impairment and comorbid mental health disorders on daily functioning: a systematic literature review

  • Edine P.J. van Munster,
  • Marjolein L.A. Onnink,
  • Lisanne B.A. Teunissen,
  • Cynthia Lamper,
  • Alida J. van der Ham,
  • Ralph de Vries,
  • Peter F.J. Verstraten,
  • Ruth M.A. van Nispen,
  • Hilde P.A. van der Aa

摘要

Background

The aim of this study was to systematically assess and discuss literature on the impact of visual impairment (VI) in combination with specific mental health disorders (MHDs), i.e. personality disorders (including antisocial, borderline and dependent personality disorder), autism spectrum disorder (ASD), obsessive-compulsive disorder and psychotic disorders, on daily functioning.

Methods

A systematic review was performed following the PRISMA-statement. The databases PubMed, Embase, CINAHL, PsycINFO, Cochrane library, and Web of Science were searched for relevant publications up to December 20th, 2024. Quality assessment was conducted following the criteria of the PHO MetaQAT. Thematic content analysis was performed to indicate the impact of VI and the chosen MHDs on daily functioning.

Results

Twenty-two relevant publications were found. Twenty-one publications described the impact of the combination of VI and ASD and sometimes additional disorders, and focused on children, predominantly in school settings. One publication addressed VI and psychosis. The impact on daily functioning was described according to age and MHD, and categorized by five main themes: (1) psychological functioning, (2) social functioning, (3) physical functioning, (4) school performance, and (5) parental and clinical support. One publication had ‘sufficient’ and ‘good’ ratings on validity, while all others had at least one ‘insufficient’ or ‘unclear’ rating.

Conclusions

A limited number of publications on the combined impact of VI and MHDs on daily functioning were found. Publications primarily focused on VI and ASD in children. Uncertainty about the impact remains due to a lack of high-quality publications. The gap in evidence calls for future research to address the challenges in supporting people with VI and MHDs.

Clinical trial number

Not applicable.